Ignite Creation Date:
2024-05-06 @ 3:05 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04513301
Status:
UNKNOWN
Last Update Posted:
2020-08-14
First Post:
2020-08-12
Brief Title:
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC EGFR - ALK - After Failure of Platinum-based Chemotherapy A RandomizedOpen Labled Phase II Clinical Study
Sponsor:
Shanghai Cancer Hospital China
Organization:
Shanghai Cancer Hospital China
Organization Data
Organization:
Shanghai Cancer Hospital China
Class:
OTHER
Study ID:
IBI308 ZL001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Cancer Hospital China
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None